Alaunos Therapeutics reported positive preclinical proof-of-concept data for ALN1003, an oral small-molecule drug candidate for treating obesity and related metabolic disorders. ALN1003 is being developed as a non-hormonal, non-incretin approach, differentiating it from hormone-based treatments like GLP-1 drugs. In two diet-induced obesity (DIO) mouse studies, ALN1003 demonstrated dose-related body weight loss, favorable body composition changes (primarily fat loss), and significant reductions in liver weight. The drug candidate also showed improvements in select biomarkers associated with liver injury (ALT, AST, ALP) and metabolic biomarkers (glucose, total cholesterol). ALN1003 was generally well tolerated in both studies, with mild, short-term, reversible hypolocomotion observed in Study 1 and slight dehydration in two high-dose mice in Study 2. The company plans further preclinical studies, formulation optimization, manufacturing refinement, and intellectual property development to support an Investigational New Drug (IND) application. As of September 30, 2025, the company had approximately $1.9 million in cash and cash equivalents, with a cash runway extending into the second quarter of 2026, and intends to seek additional financing.